| Phase 02 trials |
|
Phase 0
|
NCT05368506 |
Jul 2023 → Sep 2024 |
fallopian tube carcinoma, female breast carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1 |
OHSU Knight Cancer Institute |
Withdrawn
|
No outcome recorded
|
|
Phase 0
|
NCT04005690 |
Aug 2019 → Jun 2026 overdue |
pancreatic ductal adenocarcinoma |
OHSU Knight Cancer Institute |
Recruiting
|
No outcome recorded
|
| Phase 18 trials |
|
Phase 1
|
NCT06364410 |
Feb 2025 → Jul 2027 expected |
gastric carcinoma, gastroesophageal junction adenocarcinoma, high grade malignant neoplasm, metastatic malignant neoplasm |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06351332 |
May 2024 → Feb 2026 |
female breast carcinoma, triple-negative breast carcinoma |
Filipa Lynce, MD |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05743036 |
Feb 2023 → Jul 2024 |
colorectal cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05431582 |
Dec 2022 |
breast cancer, lung cancer, malignant pancreatic neoplasm, ovarian cancer |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT04833582 |
Aug 2021 → Aug 2023 |
osteosarcoma |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04972422 |
Jul 2021 → Jun 2022 |
cancer |
Zentera Therapeutics HK Limited |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04516447 |
Oct 2020 → Jun 2028 expected |
fallopian tube cancer, malignant epithelial tumor of ovary, peritoneum cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04158336 |
Nov 2019 → May 2025 |
cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05682170 |
Dec 2022 → Jul 2024 |
acute myeloid leukemia |
Zentalis Pharmaceuticals, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05198804 |
Jan 2022 → Oct 2025 |
fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06369155 |
Mar 2025 → Jan 2027 expected |
endometrial serous adenocarcinoma |
Joyce Liu, MD |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06015659 |
Nov 2023 → Aug 2025 overdue |
pancreatic ductal adenocarcinoma |
Brandon Huffman, MD |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05128825 |
Feb 2022 → Dec 2026 expected |
female reproductive organ cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04814108 |
Jul 2021 → Oct 2025 |
uterine cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07546500 |
Apr 2026 → May 2028 expected |
ovarian cancer |
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Recruiting
|
No outcome recorded
|